SENSEX rallies over 1,000 pts, NIFTY soars over 1% in noon deals; Marico, KRBL, Trident among buzzing stocks

The Indian benchmark indices, SENSEX and NIFTY50, surged during the afternoon session on Tuesday, November 3, bolstered by buying in capital market stocks. It was further supported by easing global crude oil prices and foreign fund inflows, which added to investor optimism.

The SENSEX soared as much as 1.4% to hit an intraday high of 76,779.66. Meanwhile, the NIFTY50 rallied as much as 1.3% to touch the session’s peak of 23,746.25.

At 12:29 PM, the S&P BSE SENSEX advanced by 1,040.34 points, or 1.37%, to trade at 76,733.12. NSE’s NIFTY50 was trading at 23,730.65, marking a 289.85-point, or 1.24%, jump.

On Monday, the foreign institutional investors (FIIs) purchased stocks worth ₹3,114.68 crore, while the domestic institutional investors (DIIs) sold equities worth ₹392.20 crore on a net basis, according to exchange data

The top gainers of the NIFTY50 index included BSE, Bharti Airtel, Tata Consumer Products, HDFC Bank, and Asian Paints.

On the flip side, Oil and Natural Gas Corporation (ONGC), Power Grid Corporation, NTPC, Reliance Industries, and Tata Steel were among the top losers.

Buzzing stocks on November 3: Check list

GRSE was leading the pack of gainers on Tuesday’s market as investors reacted to the company receiving the mega order from the Indian defence forces. The spillover impact of the order update was seen across the board of defence stocks on November 3.

The sectoral benchmark Nifty India Defence index surged 2% to hit an intraday high of 9,008.20 points on Tuesday’s market, in comparison to 8,826.65 points at the previous equity market close.

Shares of Zydus Wellness gained as much as 9.01% to hit an intraday high of ₹526.85 apiece on the National Stock Exchange (NSE) on November 3, as it reported its earnings for the July-September quarter of the 2026-27 financial year (Q2 FY27).

It posted a consolidated net profit of ₹5.1 crore in the quarter ended September 30, 2026, compared with a loss of ₹52.8 crore in the year-ago period.

Its consolidated total revenue from operations stood at ₹1,126.6 crore for the reporting quarter, marking a 73.2% year-on-year (YoY) jump from ₹650.5 crore in the second quarter of the 2025-26 fiscal year (Q2 FY26).

The stock of Trident rallied as much as 13.42% to hit an intraday high of ₹25.19 per unit on the NSE on Tuesday, November 3, after the company reported strong earnings for the September quarter of the 2026-27 financial year.

The company posted a 93.1% YoY surge in its consolidated net profit to ₹175.58 crore in Q2 FY27, compared with ₹90.93 crore in the corresponding quarter of the preceding fiscal year, according to a regulatory filing.

However, its revenue from operations declined 3.78% YoY to ₹1,719.48 crore during the quarter under review, as against ₹1,787.17 crore in the July-September quarter of FY26. The top line was impacted by a decline in the company’s revenue from the towel segment.

Marico shares jumped 8.3% to touch the session’s peak of ₹865 per unit on Tuesday, November 3, a day after the company reported a healthy September quarter and raised its FY27 guidance.

The FMCG major reported a growth of 31% in its consolidated net profit, reaching ₹550 crore for Q2 FY27, compared to ₹420 crore in the same quarter of the previous fiscal year.

Its revenue from operations for Q2 FY27 stood at ₹3,897 crore, increasing 13% YoY from ₹3,450 crore in the same period of the previous fiscal year.

In a note on Tuesday, Goldman Sachs analysts said Marico’s Q2 FY27 performance was ahead of estimates, with a strong quality of growth. They highlighted that double-digit volume growth continued, with Parachute growing 13% YoY. The analysts also noted an upgrade in the company’s FY27 and medium-term growth guidance, sustained strong growth in VAHO and the ongoing reset in Saffola edible oil.

Shares of IndiGo operator InterGlobe Aviation surged as much as 4% to hit an intraday high of ₹5,120.10 per equity share on the NSE, a day after the Supreme Court refused an urgent hearing on a plea highlighting steep increases in domestic airfares during the 2026 Diwali festive season.

According to media reports, the plea also seeks interim directions to cap fares during the current festive season and the year-end festival season. The PIL is currently listed to be heard on November 16, 2026.

Meanwhile, this week the central government has notified new rules for the aviation sector, allowing it to intervene in airline ticket prices in extraordinary situations and in the public interest, following concerns over high airfares in the backdrop of elevated crude oil and aviation turbine fuel (ATF) prices.

Experts had predicted that the Bank’s standalone net profit could rise 11 to 16% YoY to a range of ₹22,310 and ₹23,250 crore, supported by strong growth in advances and deposits.

KRBL stock gained as much as 13.72% to hit an intraday high of ₹412.80 per equity share on the NSE on Tuesday, November 3, as its consolidated net profit rose 50.44% YoY to ₹258.93 crore in Q2 FY27.

In the same period last year, the company had logged a profit of ₹172.11 crore, according to a regulatory filing.

Its revenue from operations jumped 14.3% YoY to ₹1,727.36 crore for the reporting period, as against ₹1,511.08 crore in the same period last year.

Dr. Reddy’s Lab shares rose over 1% during the trading session, after the company secured tentative US Food and Drug Administration (FDA) approval for the first generic injectable drug for HIV prevention, as the company aims to bring the affordable version of the highly effective drug to middle-income countries.

“Dr Reddy’s Laboratories has secured FDA tentative approval for the first generic injectable lenacapavir, just 16 months after Gilead’s originator product was approved for HIV prevention,” according to the official release.

The company will be looking forward to bringing the affordable version of the generic injectable lenacapavir, which will be used twice a year for HIV prevention. Lenacapavir is a medication developed by Gilead Sciences that is used to treat and prevent HIV-1 infections.

Shares of SFC Environmental Technologies, which provides wastewater treatment solutions, started trading at ₹355.10 apiece on the NSE. This reflects a premium of 7.61% over the IPO issue price of ₹330 per share. On the BSE, the stock debuted at ₹354.05 per share, up 7.29% from the issue price.

A lot consisted of 45 shares and cost ₹14,850. Investors who received SFC Environmental Technologies IPO allotment made ₹1,129.5 per lot, taking the value of their investment to ₹15,979.5, as per the listing price on the NSE.

The ₹667.53 crore IPO was a fresh issuance of 45.45 lakh shares valued at ₹150 crore and an offer-for-sale (OFS) component of up to 1.57 crore shares worth ₹517.53 crore by promoters and existing shareholders.

Shares of BLS Polymers Ltd made a robust debut on the stock exchanges on Tuesday, November 3, 2026. The stock is listed at ₹248 per share on the NSE. This reflects a premium of 65.33% over the IPO issue price of ₹150 per unit. On the BSE, it started trading at ₹244.10 apiece, up 62.73% from the issue price.

A lot consisted of 100 shares and cost ₹15,000. Investors who received BLS Polymers IPO allotment made ₹9,800 per lot, taking the value of their investment to ₹24,800, as per the listing price on the NSE.

The ₹255 crore IPO was a completely fresh issuance of 1.7 crore shares, with no OFS component.